Priv.-Doz. Mag. DDr. Klaus Podar

Programmleiter "Multiples Myelom", Oberarzt am Universitätsklinikum Krems

+43 2732 9004 2555

klaus.podar@kl.ac.at

Publikationen

2020
- Konferenzbeitrag
  - Ludwig, H., Sormann, S., Zojer, N., Andel, J., Hartmann, B.L., Tinchon, C., Gunsilius, E., Podar, K., Egle, A., Willenbacher, W., Woll, E., Ruckser, R., Bozic, B., Krauth, M.-T., Petzer, A., Schmitt, C.A., Machherndl-Spandl, S., Agis, H., Fillitz, M., Paiva, B. & Greil, R., 2020. Poster: Carfilzomib in combination with either Rd or Td overcomes the negative impact of HR cytogenetics in NDMM. Interim efficacy analysis of combined data of KRd vs. KTd followed by K maintenance or control. In 25th Congress of the European Hematology Association (EHA). COVID-19 Online.
- Zeitschriftenartikel
  - Podar, K., Shah, J., Chari, A., Richardson, P.G. & Jagannath, S., 2020. Selinexor for the treatment of multiple myeloma. Expert opinion on pharmacotherapy, S.1-10.
    Link
- Andere wissenschaftliche Beiträge
  - Podar, K., 2020. Stellenwert der autologen Stammzelltransplantation beim multiplen Myelom. JATROS Hämatologie & Onkologie, (2), S.6-9.
2019
- Konferenzbeitrag
  - Fan, F., Malvestiti, S., Shen, Y., Morelli, E., Mishima, Y., Seckinger, A., Hose, D., Bakiri, L., Vallet, S., Sattler, M., Roccaro, A.M., Goldschmidt, H., Percherstorfer, M., Sun, C., Hu, Y., Wagner, E.F., Tassone, P., Ghobrial, I.M., Jaeger, D. & Podar, K., 2019. Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis. In American Society of Hematology, 61th Annual Meeting, scientific session. Orlando, FL.
    Link
  - Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Bakiri, L., Wagner, E.F., Sattler, M., Pecherstorfer, M. & Podar, K., 2019. Poster: Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy. In 17th International Myeloma Workshop. Boston.
  - Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Sattler, M., Bakiri, L., Wagner, E.F., Percherstorfer, M. & Podar, K., 2019. Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy. In American Society of Hematology, 61th Annual Meeting, scientific session. Orlando, FL.
    Link
  - Ludwig, H., Sormann, S., Zojer, N., Andel, J., Hartmann, B.L., Tinchon, C., Gunsilius, E., Podar, K., Egle, A., Willenbacher, W., Woll, E., Ruckser, R., Bozic, B., Krauth, M.-T., Petzer, A., Schmitt, C.A., Machherndl-Spandl, S., Agis, H., Paiva, B. & Greil, R., 2019. Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Ef. In American Society of Hematology, 61th Annual Meeting, scientific session. Orlando, FL.
    Link
  - Podar, K., 2019. Multiples Myelom II. In DGHO, OeGHO, SGMO & SGH 2019 (Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie). Berlin.
  - Podar, K., 2019. Präsentation: Klinisch relevante Arzneimittelinteraktionen im Multiplen Myelom. In Hämatologie im Wandel der Zeit . 28.-29.06.2019. Wien.
  - Podar, K., 2019. Präsentation: Stellenwert der Autologen Stammzelltransplantation beim Multiplen Myelom. In 9. Niederösterreichischer Onkologietag. Krems.
  - Podar, K., 2019. Presentation: Targeting transcription factors for cancer therapy: evolving therapeutic strategies . In 9. Niederösterreichischer Onkologietag. Krems.
- Zeitschriftenartikel
  - Chari, A., Vogl, D.T., Gavriatopoulou, M., Nooka, A.K., Yee, A.J., Huff, C.A., Moreau, P., Dingli, D., Cole, C., Lonial, S., Dimopoulos, M., A. Stewart, K., Richter, J., Vij, R., Tuchman, S., Raab, M.S., Weisel, K.C., Delforge, M., Cornell, R.F., Kaminetzky, D., Hoffman, J.E., Costa, L.J., Parker, T.L., Levy, M., Schreder, M., Meuleman, N., Frenzel, L., Mohty, M., Choquet, S., Schiller, G., Comenzo, R.L., Engelhardt, M., Illmer, T., Vlummens, P., Doyen, C., Facon, T., Karlin, L., Perrot, A., Podar, K., Kauffman, M.G., Shacham, S., Li, L., Tang, S., Picklesimer, C., Saint-Martin, J.-R., Crochiere, M., Chang, H., Parekh, S., Landesman, Y., Shah, J., Richardson, P.G. & Jagannath, S., 2019. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. The New England journal of medicine, 381, S.727-738.
  - Li, S., Vallet, S., Sacco, A., Roccaro, A., Lentzsch, S. & Podar, K., 2019. Targeting transcription factors in multiple myeloma: evolving therapeutic strategies. Expert opinion on investigational drugs, 28, S.445-462.
    Link
  - Lind, J., Czernilofsky, F., Vallet, S. & Podar, K., 2019. Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert opinion on emerging drugs, 24, S.133-152.
    Link
  - Vallet, S., Fan, F., Malvestiti, S., Pecherstorfer, M., Sattler, M., Schneeweiss, A., Schulze-Bergkamen, H., Opferman, J.T., Cardone, M.H., Jager, D. & Podar, K., 2019. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Breast cancer research and treatment, 173, S.585-596.
    Link
2018
- Konferenzbeitrag
  - Malvestiti, S., Fan, F., Bashari, H.M., Morelli, E., Seckinger, A., Hose, D., Goldschmidt, H., Zoernig, I., Bakiri, L., Sattler, M., Vallet, S., Pecherstorfer, M., Wagner, E.F., Tassone, P., Jaeger, D. & Podar, K., 2018. Poster: Multiple myeloma pathogenesis: The role of JunB in bone marrow angiogenesis. In 23rd Congress of the European Hematology Association (EHA). Stockholm, Sweden.
  - Podar, K., 2018. Presentation: Transcription factors in multiple myeloma: new potential targets. In 4th Multiple Myeloma and related malignancies. Bari, Italy.
  - Podar, K., 2018. Therapiefortschritte – Hämato-Onkologie im Jahr 2018: Multiples Myelom. In 8. Niederösterreichischer Onkologietag. Krems.
- Zeitschriftenartikel
  - Breitkreutz, I., Podar, K., Figueroa-Vazquez, V., Wilhelm, S., Hayden, P.J., Anderson, K.C. & Raab, M.S., 2018. The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. Annals of Hematology, 97, S.839-849.
    Link
  - Podar, K., 2018. Choosing an appropriate salvage therapy for a patient with multiple myeloma. Expert Opinion on Pharmacotherapy, 19, S.1511-1516.
  - Vallet, S., Fan, F., Malvestiti, S., Pecherstorfer, M., Sattler, M., Schneeweiss, A., Schulze-Bergkamen, H., Opferman, J.T., Cardone, M.H., Jager, D. & Podar, K., 2018. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Breast Cancer Research and Treatment.
    Link
  - Vallet, S., Filzmoser, J.M., Pecherstorfer, M. & Podar, K., 2018. Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies. Pharmaceutics, 10, S.202.
  - Vallet, S., Hoyle, N.R., Kyle, R.A., Podar, K. & Pecherstorfer, M., 2018. A role for bone turnover markers beta-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. Leukemia & Lymphoma, 59, S.2431-2438.
    Link
- Andere wissenschaftliche Beiträge
  - Podar, K., 2018. Immunmodulierende Medikamente bleiben essenzielle Basis der Therapie. JATROS Hämatologie & Onkologie, (5), S.41.
  - Podar, K., 2018. Teamwork gegen Krebs. Gesund leben in Niederösterreich, (6), S.30-32.
2017
- Zeitschriftenartikel
  - Bhanot, H., Weisberg, E.L., Reddy, M.M., Nonami, A., Neuberg, D., Stone, R.M., Podar, K., Salgia, R., Griffin, J.D. & Sattler, M., 2017. Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget, 8, S.67639-67650.
  - Fan, F., Bashari, M.H., Morelli, E., Tonon, G., Malvestiti, S., Vallet, S., Jarahian, M., Seckinger, A., Hose, D., Bakiri, L., Sun, C., Hu, Y., Ball, C.R., Glimm, H., Sattler, M., Goldschmidt, H., Wagner, E.F., Tassone, P., Jaeger, D. & Podar, K., 2017. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. Leukemia, 31, S.1570-1581.
    Link
  - Podar, K. & Jager, D., 2017. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma. Current Cancer Drug Targets, 17, S.782-805.
    Link
  - Podar, K. & Pecherstorfer, M., 2017. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opinion on Pharmacotherapy, 18, S.1061-1079.
    Link
  - Vallet, S., Pecherstorfer, M. & Podar, K., 2017. Adoptive cell therapy in multiple Myeloma. Expert Opinion on Biological Therapy, 17, S.1511-1522.
    Link

Forschungsprojekte

JunB im Multiplen Myelom
Pathophysiologische Rolle von JunB im Multiplen Myelom
- Projektnummer: WST3-F-5031298/002-2018
- Projektleitung: Klaus Podar, Karl Landsteiner Privatuniversität für Gesundheitswissenschaften / Molekulare Hämatologie / Onkologie, Klaus Podar, Karl Landsteiner Privatuniversität für Gesundheitswissenschaften / Klinische Abteilung für Innere Medizin 2 (UK Krems)
- Projektpartner: The Antibody Lab GmbH, IMC FH Krems, Universität für Veterinärmedizin Wien / Institut für Pharmakologie und Toxikologie
- Projektlaufzeit: 24 Monate ab 01.10.2018
Hintergrund
Microenvironment-induced signaling pathways regulate the activity of numerous transcription factors (TFs). Approaches to target TFs are among the most promising novel anticancer strategies with a potentially high therapeutic index. Our recent data indicated a key role for the AP-1 family member JunB in MM pathogenesis (Fan et al., Leukemia 2017). In continuation of these findings, the proposed project aims to further define JunB as a novel therapeutic target in MM, and to thereby set the pace for the development of direct or indirect JunB inhibitors in order to further improve patient outcome.
Dieses Projekt wird aus Mitteln des Europäischen Fonds für regionale Entwicklung (EFRE) kofinanziert. Nähere Informationen zu IWB/EFRE finden Sie auf www.efre.gv.at

Informationen für

Publikationen

2020

Konferenzbeitrag

Zeitschriftenartikel

Andere wissenschaftliche Beiträge

2019

Konferenzbeitrag

Zeitschriftenartikel

2018

Konferenzbeitrag

Zeitschriftenartikel

Andere wissenschaftliche Beiträge

2017

Zeitschriftenartikel

Forschungsprojekte

JunB im Multiplen Myelom

Hintergrund

Aktuelles

Forum Alpbach "Wasser - der Ursprung allen Lebens": mit Andreas Farnleitner

Neuer Hinweis auf eingeschränkte Immunität nach Covid-19-Genesung

KL startet Grundlagenforschung zu Schwindelgefühl und Hörverlust

Events

INFO TALK Psychologie

Europäisches Forum Alpach: Wasser & Gesundheit

Internationales Skills Lab Symposium 2020 - ABGESAGT

Kontakt